Squash Bug Trap & Frost in June - Back to the Homestead
We are moving along. The bean and pea seeds that I replanted in the bare spots of the rows are starting to come back. I took your advice and held off on watering them for a while but nature keeps interfering with my plans (not complaining at all). It's strange how some plants need more water than others. They are greening up a bit but I am still keeping an eye on them.
This video has a kaleidoscope of topics: Frost, Green Beans, Rain, Wind, Squash Bugs, Duckweed and...well...there's got to be a topic or two that I could squeeze in there. We had a big storm come through the area and blew...well...like it blows in Idaho. There sure is no shortage of wind here in the potato state.
You'll see in this video:
1. Wind on the Homestead
2. Duckweed Update
3. Building a Squash Bug Trap
4. Frost in June
I have another experiment that I am going to try. Stink bugs and squash bugs look so much alike to me. I know they share some similarities. According to http://bugguide.net/node/view/182:
The stink bug's classification is as follows:
Classification
Kingdom Animalia (Animals)
Phylum Arthropoda (Arthropods)
Class Insecta (Insects)
Order Hemiptera (True Bugs, Cicadas, Hoppers, Aphids and Allies)
Suborder Heteroptera (True Bugs)
Superfamily Pentatomoidea
Family Pentatomidae (Stink Bugs)
The squash bug's classification is as follows:
Classification
Kingdom Animalia (Animals)
Phylum Arthropoda (Arthropods)
Class Insecta (Insects)
Order Hemiptera (True Bugs, Cicadas, Hoppers, Aphids and Allies)
Suborder Heteroptera (True Bugs)
Superfamily Coreoidea
Family Coreidae (Leaf-footed Bugs)
Subfamily Coreinae
Tribe Coreini
Genus Anasa (Squash Bugs)
In this week's video, I demonstrate setting up the squash bug trap. I will check it every day until I start getting some bugs in the trap (or not) and let you know how it turns out on subsequent videos.
Here's a link to the video where I got the idea: http://www.youtube.com/watch?v=zKc5acECuQk
Lastly, I have a video I uploaded called, "Video Response to Strong Points during SHTF or DHTO - Back to the Homestead." I was tagged in a video and posted my response...
Enjoy!
EGFR TKI resistance mechanisms and c-Met inhibitors will become a hot spot
ReplyDeleteEGFR mutations in patients with EGFR TKI gradually determine the first-line treatment of status, the EGFR TKI get drug resistance mechanism of their resistance should be taken treatment strategies will gradually become the focus of attention.
The EGFR TKI acquired resistance mechanisms are not yet completely clear. Previous studies show that approximately 50% of patients after EGFR TKI treatment after acquired drug resistance may be due to tumor cells secondary mutation. This resistance mutation No. 790 sites in the EGFR gene on the 20th exon methionine is substituted with threonine (T790M mutation), thus impeding the EGFR with erlotinib combination of erlotinib or gefitinib, erlotinib, or increase in the affinity of the EGFR and its ligands ATP.
EGFR TKI acquired drug resistance in patients with no standard treatment options. EGFR TKI combined with chemotherapy, the 3rd generation EGFR TKI, second-generation EGFR TKI United Cistercian infliximab, second-generation EGFR TKI inhibitor of c-Met, the second generation the EGFR TKI United HDAC inhibitors as well as second-generation EGFR TKI United IFGF1RC inhibitors future promising drug post-processing program.
The basis of studies have shown that a new generation of irreversible EGFR inhibitors may be acquired resistance to EGFR TKI patients. EKB-569, HKI-272, Canertinib, BIBW2992 and PF-299804 and other ongoing human clinical trials of drugs.
c-Met is leading to tumor formation and metastasis of many passage cross point, the c-Met as a target can be relatively easily achieved while interference for many passages, to find efficient c-Met inhibitor antineoplastic study hot spots. Currently, capable of blocking the signal transduction pathway of c-Met has been found that many compounds, including monoclonal antibodies (such as OA-505) and small molecule kinase inhibitor of c-Met (e.g., PF-2341066, ARQ-197, XL-184 etc.). 2010 ESMO annual meeting of the multi-center, randomized, double-blind Ⅱ clinical study (OAM4588) of the Met receptor antagonist (MetMab) combined with erlotinib efficacy of the treatment of patients with advanced NSCLC. The results showed that highly expressed in the Met patients, the erlotinib Nigeria United MetMab can improve PFS and OS, and no unexpected adverse reactions, but in patients with low expression Met erlotinib Stock MetMab of group PFS and OS was poor.
Medchemexpress Can provide the above product,its website:www.medchemexpress.com
Tandutinib
KW-2449
Quizartinib
AST 487
Linifanib
Canertinib
Canertinib dihydrochloride
CP-724714 (E-Double bond)
2-Methoxyestradiol
GSK1904529A